ReviewJournal of the Chinese Medical Association : JCMA2026
The evolution of renal cell carcinoma classification.
Review in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precise classification of diseases is essential for precision medicine to develop efficient, personalized treatments for cancer. Progress in renal cell carcinoma (RCC) classification is a paradigm that demonstrates how precise classification is achieved. RCC classification has evolved from purely morphological criteria to the sophisticated application of various laboratory modalities. With advancing techniques and multi-institutional collaboration, the latest World Health Organization (WHO) classification takes into account decades of studies on the nature of RCC, and is subsequently divided into six categories: clear cell renal tumors, papillary renal tumors, oncocytic and chromophobe renal tumors, collecting duct tumors, other renal tumors, and molecularly defined renal carcinomas. This review provides a historical perspective on how the current WHO classification was attained, followed by a compendium of different RCC types and their salient characteristics, including histopathological features, clinicopathological correlations, and molecular distinctiveness. This information should be shared among pathologists and clinicians to better translate pathological findings into effective clinical practice in terms of diagnosis, prognostication, and therapeutic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.